000279496 001__ 279496
000279496 005__ 20250709100939.0
000279496 037__ $$aDZNE-2025-00823
000279496 1001_ $$0P:(DE-2719)2810938$$aMüller, Stephan A$$b0$$udzne
000279496 245__ $$aDataset: Proteomics of ADAM17 and iRhom2 KO microglia using high-performance secretome protein enrichment with click sugars
000279496 260__ $$bPRoteomics IDEntifications Database$$c2025
000279496 3367_ $$2BibTeX$$aMISC
000279496 3367_ $$0PUB:(DE-HGF)32$$2PUB:(DE-HGF)$$aDataset$$bdataset$$mdataset$$s1752047404_8071
000279496 3367_ $$026$$2EndNote$$aChart or Table
000279496 3367_ $$2DataCite$$aDataset
000279496 3367_ $$2ORCID$$aDATA_SET
000279496 3367_ $$2DINI$$aResearchData
000279496 520__ $$aThe cell surface receptor TREM2 is a key genetic risk factor and drug target in Alzheimer’s disease (AD). In the brain, TREM2 is expressed in microglia, where it undergoes proteolytic cleavage, linked to AD risk, but the responsible protease in microglia is unknown. Another microglia-expressed AD risk factor is inactive rhomboid 2 (iRhom2, RHBDF2), which acts as a non-catalytic subunit of the metalloprotease ADAM17. Its function in AD is unknown. To determine whether loss of iRhom2 and ADAM17 leads to a reduction of cleavage of additional membrane proteins beyond TNF, we used the ‘high-performance secretome protein enrichment with click sugars’ (hiSPECS) method for mass spectrometry-based secretome analysis (Tüshaus et al, 2020). hiSPECS uses a metabolic labeling with click sugars, which allows to culture cells in the presence of serum or serum-like supplements. Therefore, we have used the murine microglia of wild-type and RHBDF2/iRhom2 KO mice.
000279496 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000279496 7001_ $$0P:(DE-2719)2181459$$aLichtenthaler, Stefan$$b1$$udzne
000279496 7870_ $$0DZNE-2025-00430$$aJocher, Georg et.al.$$dHeidelberg : EMBO Press, 2025$$iRelatedTo$$r$$tThe late-onset Alzheimer’s disease risk factor RHBDF2 is a modifier of microglial TREM2 proteolysis
000279496 8564_ $$uhttps://wwwdev.ebi.ac.uk/pride/archive/projects/PXD054898
000279496 909CO $$ooai:pub.dzne.de:279496$$pVDB
000279496 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810938$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000279496 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2181459$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000279496 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000279496 9141_ $$y2025
000279496 9201_ $$0I:(DE-2719)1110006$$kAG Lichtenthaler$$lNeuroproteomics$$x0
000279496 980__ $$adataset
000279496 980__ $$aVDB
000279496 980__ $$aI:(DE-2719)1110006
000279496 980__ $$aUNRESTRICTED